Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $615.11 million, and the earnings are expected to come in at ...

On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...

Now, it’s worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 196% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund underperformed and generated a net ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

Zooming in on the latest balance sheet data, we can see that Bio-Rad Laboratories had liabilities of US$613.7m due within 12 months and liabilities of US$3.15b due beyond that. Offsetting these ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -6.31% in ...

Biodesix expands its Bio-Rad partnership to validate ddPCR cancer assays, starting with ESR1 mutation testing in breast cancer.

Bio-Rad Laboratories (NYS: BIO) is expected to report Q1 earnings on May 7. Here's what Wall Street wants to see: Comparing the upcoming quarter to the prior-year quarter, average analyst estimates ...

For the quarter ended Dec. 31 (Q4), Bio-Rad Laboratories beat expectations on revenues and crushed expectations on earnings per share. Compared to the prior-year quarter, revenue grew. Non-GAAP ...

Bio-Rad Laboratories (NYSE: BIO) reported earnings on May 7. Here are the numbers you need to know. The 10-second takeaway For the quarter ended March 31 (Q1), Bio-Rad Laboratories met expectations on ...